AnaptysBio Q2FY26 Results: Adj. EPS beats est, sales up 23%
- Adjusted EPS of $(0.11) beat consensus estimate of $(0.46) by 76%
- Q2FY26 sales rose 23% YoY to $27.5 million, beating $21.7M estimate
- Net income surged to $177.3 million driven by $181.5 million tax benefit
- G&A expenses tripled to $16.0 million due to legal costs and separation
*this image is generated using AI for illustrative purposes only.
AnaptysBio (NASDAQ: ANAB) reported second-quarter fiscal 2026 adjusted earnings per share of $(0.11), beating the analyst consensus estimate of $(0.46) by 76.09 percent. The company’s quarterly sales reached $27.5 million, surpassing the $21.675 million estimate by 26.82 percent and rising 23 percent year-over-year.
The top-line growth was primarily fueled by a 25 percent increase in Jemperli royalties, partially offset by the absence of $9.7 million in revenue from the Vanda license agreement recognized in the prior year period. Collaboration revenue for the six months ended June 30, 2026, increased 6 percent to $53.0 million.
Financial Performance
Despite the revenue beat, the company reported a net income of $177.3 million for the quarter, a significant surge from $5.7 million in Q2FY25. This bottom-line expansion was non-operational, driven by a $181.5 million tax benefit from continuing operations following the release of valuation allowance on deferred tax assets after separating from First Tracks Biotherapeutics.
Operating performance showed mixed signals. General and administrative expenses expanded to $16.0 million, up from $4.0 million in the prior year, due to legal costs associated with the corporate separation and ongoing litigation with GSK and Tesaro. Research and development expenses from continuing operations registered a negative balance of $2.7 million, reflecting adjustments related to clinical contract closeouts.
| Metric | Q2FY26 | Q2FY25 | Change |
|---|---|---|---|
| Collaboration Revenue | $27.5 million | $22.3 million | +23% |
| General & Administrative Expenses | $16.0 million | $4.0 million | +300% |
| R&D Expenses (Continuing Ops) | $(2.7) million | $(1.7) million | N/A |
| Net Income (Continuing Ops) | $177.3 million | $5.7 million | +2,099% |
What the Numbers Show
The divergence between operational metrics and net income is stark. While adjusted EPS beat estimates, indicating better-than-expected cost management or revenue realization relative to analyst models, the reported net profit is almost entirely accounting-driven. The company recorded an operating income of just $14.1 million and a loss before taxes of $4.2 million. The subsequent $181.5 million tax benefit reversed this pre-tax loss into substantial net profitability, highlighting that core operational cash generation remains distinct from the bottom-line accounting result.
Balance Sheet & Cash Position
Cash, cash equivalents, and investments stood at $164.1 million as of June 30, 2026, down from $211.6 million at the end of December 2025. The decrease was driven by $72.9 million used in operating activities, partially offset by $25.4 million received from stock option exercises.
The liability related to the sale of future royalties decreased to $256.5 million from $276.5 million. Anaptys estimates that Sagard has accrued approximately $301 million in royalties and sales milestones through Q2FY26, with the remaining ~$299 million non-recourse debt monetization anticipated to be paid down in the second half of 2027.
Business Updates
Jemperli global net sales reached $644 million for the six months ended June 30, 2026, representing 34 percent year-over-year growth. GSK announced positive interim results from the pivotal AZUR-1 trial in July 2026, meeting its primary objective for dostarlimab monotherapy in rectal cancer. The FDA has assigned a PDUFA action date of February 2027, with eligibility for expedited review via the National Priority Voucher program.
Regarding the litigation with GSK and Tesaro, the trial concluded in July 2026. A post-trial hearing is scheduled for October 20, 2026, with a judgment expected in Q4FY26 or Q1FY27. Additionally, the FDA target action date for Quimilza in generalized pustular psoriasis is set for December 12, 2026.
How might the outcome of the October 20 post-trial hearing regarding the GSK and Tesaro litigation impact AnaptysBio's future G&A expenses and legal risk profile?
Given the $181.5 million non-operational tax benefit, what is AnaptysBio's projected operating cash burn rate for the remainder of fiscal 2026, and is the current $164.1 million cash position sufficient to fund operations without dilution?
Will the FDA's February 2027 PDUFA date for dostarlimab in rectal cancer accelerate royalty inflows from Jemperli, or could potential label restrictions limit long-term revenue growth?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
